HemosIL Chromogenic Factor IX Receives 510(k)-Clearance from US FDA and CE Mark in Europe

Werfen has received 510(k) clearance from the US Food and Drug Administration (FDA), and CE Mark (based on compliance with the In Vitro Diagnostic Regulation (IVDR)), for the HemosIL Chromogenic Factor IX assay,

 enabling commercialization in US and Europe. A validated, automated solution for factor IX activity testing, this  assay uses a chromogenic method to identify patients with factor IX

deficiency, measure factor IX activity levels, and estimate the potency of factor IX drugs, on ACL TOP Family/50 Series/70 Series Hemostasis Testing Systems.

Hemophilia B is one of the most common factor deficiency disorders, caused by low or absent levels of factor IX activity. Newer factor concentrates to treat patients with Hemophilia B behave differently than traditional concentrates in the laboratory, highlighting the need for targeted laboratory measurement capabilities, to ensure a high standard of patient care. 

The release of the HemosIL Chromogenic Factor IX assay demonstrates Werfen’s commitment to meeting the latest challenges for Hemostasis laboratories.

Congratulations to all of the teams involved for their unwavering dedication to achieving this milestone, which will undoubtedly Power Patient Care!

EEMEA Marketing Team

Last modified on Tuesday, 24 February 2026 11:37

 

All rights reserved. © werfen.com

Get in touch

with the EEMEA team:

eemea@werfen.com

 

werfenplain

Issues

Go to top